

1 **Title:** Simple visualization of submicroscopic protein clusters with a phase-separation-based
2 fluorescent reporter.

3
4 **Authors:** Thomas R. Mumford¹, Diarmid Rae¹, Emily Brackhahn², Abbas Idris¹, David Gonzalez-
5 Martinez¹, Ayush Aditya Pal¹, Michael C. Chung³, Juan Guan^{3,4}, Elizabeth Rhoades^{2,5}, Lukasz J.
6 Bugaj^{1,6,7*}

7
8 **Affiliations:**

9 ¹Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA

10 ²Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA

11 ³Department of Physics, University of Florida, Gainesville, FL 32611

12 ⁴Department of Anatomy and Cell Biology, University of Florida, Gainesville, FL 32611

13 ⁵Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine,

14 University of Pennsylvania, Philadelphia, PA, 19104, USA

15 ⁶Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA

16 ⁷Institute of Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

17
18 *corresponding author, Lead Contact

19
20 **Correspondence:** bugaj@seas.upenn.edu

21
22 **ABSTRACT:**

23 Protein clustering plays numerous roles in cell physiology and disease. However, protein
24 oligomers can be difficult to detect because they are often too small to appear as puncta in
25 conventional fluorescence microscopy. Here we describe a fluorescent reporter strategy that
26 detects protein clusters with high sensitivity, called CluMPS (Clusters Magnified by Phase
27 Separation). A CluMPS reporter detects and visually amplifies even small clusters of a binding
28 partner, generating large, quantifiable fluorescence condensates. We use computational
29 modeling and optogenetic clustering to demonstrate that CluMPS can detect small oligomers and
30 behaves rationally according to key system parameters. CluMPS detected small aggregates of
31 pathological proteins where the corresponding GFP fusions appeared diffuse. CluMPS also
32 detected and tracked clusters of unmodified and tagged endogenous proteins, and orthogonal
33 CluMPS probes could be multiplexed in cells. CluMPS provides a powerful yet straightforward
34 approach to observe higher-order protein assembly in its native cellular context.

35 **Introduction**

36 Protein clustering is ubiquitous and plays important roles throughout normal and disease
37 physiology¹⁻⁴. Processes including transmembrane receptor signaling, transcription factor
38 activation, and cellular stress responses all depend on the appropriate formation of protein
39 clusters⁵⁻⁹. Aberrant clustering, in turn, has been linked with numerous pathologies, including in
40 neurodegenerative diseases, cancer, and aging^{11,14,16,18,20,22,24,26,71,74}.

41
42 Clustering is driven by multivalent interactions whose characteristics generate diverse
43 biophysical, biochemical, and functional outcomes^{3,10,12}. Protein assemblies can serve many
44 functions, including enhancing biochemical reaction rates, sequestering proteins, spatially
45 restricting biochemical reactions, and buffering concentrations of cellular components^{4,12,13,15}.
46 Such assemblies can also play roles in cell signal processing, enabling ultra-sensitivity,
47 bistability, and memory^{2,17,19}. A deeper understanding of when/where protein clustering occurs
48 will not only paint a clearer picture of cellular organization and function but will also provide novel
49 control nodes where clustering can be modulated to regulate cell behavior for biomedicine and
50 biotechnology.

51
52 It is currently challenging to understand the extent of protein clustering in cells because we lack
53 straightforward tools to observe it. Physiologically relevant clusters are often too small to see
54 using light microscopy^{21,23,25,27,28}. The toxic “soluble oligomers” of α -synuclein, amyloid- β , and
55 TDP-43 found in neurodegenerative diseases consist of only 10s of monomers, in assemblies
56 roughly 10-100 nm in size^{14,16,39,42,71,72}. In signaling, protein nanoclusters transduce signals from
57 activated T cell receptors³¹, and ~100 nm clusters of scaffold proteins compartmentalize protein
58 kinase A activity³². Moreover, it is estimated that most proteins form homo-oligomers³³, and that
59 at least 18% of the human proteome is organized into condensates $>\sim 100$ nm in size³⁴. Direct
60 observation of such small clusters is often not possible with simple fluorescent protein fusions
61 because the clusters do not concentrate enough fluorophores to exceed the fluorescence
62 background. This principle is demonstrated by *A. thaliana* Cryptochrome 2 (Cry2), which clusters
63 upon blue light stimulation³⁵. Cry2 cluster size is a function of its concentration, and below a
64 certain concentration, clusters of fluorescent fusions of Cry2 do not appear^{35,50}. Nevertheless,
65 small clusters continue to form in this low concentration regime, evidenced by the fact that
66 certain optogenetic tools based on Cry2 clustering can still be activated despite the absence of
67 visible clusters^{34,53}. Additionally, large Cry2 clusters can be generated at low concentrations by
68 co-expression with multivalent binding partners³⁸⁻⁴⁷ or by appending Cry2 with certain peptides
69 or disordered regions^{38,40,41,43-49,50}, suggesting that small clusters are forming in the absence of
70 these additional domains.

71
72 Specialized microscopy methods exist to observe such small clusters, including Foerster
73 resonance energy transfer (FRET), fluorescence anisotropy, fluorescence correlation
74 spectroscopy, and super-resolution imaging. However, these methods are subject to drawbacks
75 including complexity in acquisition and analysis, low signal-to-noise ratio, significant optimization
76 for each target, long acquisition times that obscure fast dynamic changes, or the need for protein
77 overexpression⁵¹. Overexpression can yield artifacts because clustering is non-linearly
78 dependent on concentration, thus raising questions of whether the observed clustering is
79 representative of the native cellular context^{67,69}.

80
81 We sought to address this challenge with a fluorescent reporter of protein clustering that 1) could
82 detect small clusters, 2) is simple to design and image, 3) is easily adaptable to new targets, 4)
83 could report on endogenous targets, and 5) could be rapidly imaged in live mammalian cells.
84 Here we introduce such a reporter strategy called CluMPS (Clusters Magnified via Phase
85 Separation). CluMPS is a multivalent fluorescent reporter that detects and amplifies clusters of a

86 target protein, producing large phase-separated condensates that can be easily measured.
87 Combining live cell imaging, optogenetic clustering, and stochastic modeling, we validated the
88 CluMPS approach, demonstrated its sensitivity to small clusters, and determined critical system
89 features required for CluMPS activation. We then demonstrated that CluMPS can visualize
90 diverse pathological clusters that otherwise appear diffuse, including those of endogenous
91 proteins, can report on drug-induced cluster dynamics, and can be multiplexed to visualize
92 distinct clustered species in the same cell. Our work thus provides a modular reporter strategy
93 for sensitive and dynamic observation of protein clusters in mammalian cells.
94

95 **Results**

96 **Design of the CluMPS reporter.** The CluMPS reporter leverages phase separation to detect
97 and visually amplify small protein clusters. We chose phase separation as a readout due to its
98 sensitivity and simplicity: phase separation can arise from multivalent interactions of even trimers
99 and tetramers⁶⁹, resulting in micron-scale condensates that are easy to detect.
100

101 A CluMPS reporter is multivalent and has affinity for a target protein of interest. If the target is
102 clustered, CluMPS and the target condense together into large fluorescent puncta. Otherwise,
103 CluMPS remains diffuse (**Figure 1A**). Such conditional condensation of CluMPS could be
104 triggered by even small oligomers of its target, allowing CluMPS to report on otherwise invisible
105 protein clusters. CluMPS thus would provide a straightforward and modular method to detect
106 submicroscopic clustering in live cells and could be readily adapted to report on endogenous
107 proteins, thus fulfilling our design criteria.
108

109 A CluMPS reporter consists of three domains: 1) a binding domain for a target protein, 2) a
110 fluorescent protein, and 3) an amplification domain that provides multivalency (**Figure 1B**). We
111 tested five candidate amplification domains — two multimeric coiled-coils (hexameric HOTag3
112 and tetrameric HOTag6)⁵⁷ and three intrinsically disordered regions (IDR: FUS(LC), LAF-1 RGG,
113 Xvelo)⁵⁷ — and we assayed their ability to enable amplification of small clusters of GFP. To
114 target GFP, we used the GFP-binding nanobody LaG17 as the binding domain⁵⁸.
115

116 To benchmark the performance of our candidate CluMPS designs, we used an optogenetic
117 approach to induce aggregation of GFP. We fused GFP to Cry2, which forms clusters under
118 blue light stimulation^{37,52,59} (**Figure 1C**). The size of light-induced Cry2 clusters depends on
119 concentration^{36,50,77}. While Cry2-GFP forms large, visible clusters under high expression, clusters
120 in low-expressing cells are too small to observe above the diffuse fluorescence background
121 (**Figure 1D,E**). Such small unobservable clusters provided an ideal test-case for CluMPS
122 amplification.
123

124 We tested the ability of candidate CluMPS constructs to form protein condensates when co-
125 expressed with Cry2-GFP and stimulated with blue light. When expressed alone or with Cry2-
126 GFP in the dark, all CluMPS variants showed diffuse expression (**Figure 1F, top panels**,
127 **Supplementary Figure 1A-C**, **Supplementary Video 1**, **Supplementary Figure 2**). Upon light
128 stimulation, CluMPS variants with disordered amplification domains showed little or no phase
129 separation, comparable to the negative control (LaG17-mCh with no amplification domain). By
130 contrast, constructs with multimeric amplification domains (HOTag3 or HOTag6) formed large
131 condensates within 10s of seconds of stimulation (**Figure 1F**, **Supplementary Figure 1A-C**,
132 **Supplementary Video 1**). CluMPS condensation could be observed at all concentrations of
133 Cry2-GFP, including at low levels (**Figure 1G**). Thus, we identified at least two distinct
134 amplification domains that could be used to implement the CluMPS approach. We used
135 HOTag3 (6-mer) as the amplification domain for subsequent experiments, unless otherwise
136 noted.

137
138 To determine if CluMPS could amplify other multivalent species, we co-expressed the LaG17-
139 mCh-HOTag3 construct (LaG17-CluMPS) with a concatamer of five tandem GFP molecules
140 (GFPx5), which appeared diffuse when expressed alone (**Supplementary Figure 3A,B**).
141 CluMPS showed robust condensation in cells where it was co-expressed with GFPx5.
142 (**Supplementary Figure 3C, D**). GFP concatamers were pentameric in cells and were not
143 spontaneously forming higher order assemblies, as validated through in-cell fluorescence
144 correlation spectroscopy (**Supplementary Figure 4**). To demonstrate CluMPS against a non-
145 GFP target, we tested its activity against concatamers of the small ALFA peptide tag⁶⁰. We
146 replaced LaG17 with a nanobody against ALFA (nbALFA-CluMPS), and we concatamerized four
147 ALFA tags on a single peptide chain as the multivalent target (ALFAx4) (**Supplementary Figure**
148 **3E**). NbALFA-CluMPS was diffuse when expressed alone but formed micron-scale condensates
149 when co-expressed with ALFAx4 (**Supplementary Figure 3F-H**). Thus CluMPS is a
150 generalizable approach to detect multivalency in even small assemblies of proteins.
151
152 We considered whether CluMPS could report false positives, for example by phase separating
153 with a target that is not constitutively multivalent but had a weak intrinsic propensity to self-
154 associate. To test this possibility, we observed whether LaG17-CluMPS would phase separate
155 with a fusion of GFP with either FUS(LC) or RGG, two disordered domains that are not
156 multimeric but that have sufficient self-affinity to drive phase separation at high concentration or
157 when multimerized⁵⁶. In both cases, CluMPS did not induce phase separation at any expression
158 level of the GFP fusions (**Supplementary Figure 5**). Thus, while CluMPS is activated by small
159 clusters, we do not observe activation by monomers, even those with a latent ability to
160 multimerize.
161
162 We also tested whether CluMPS could report on the dynamics of clustering by measuring
163 CluMPS reversion to a diffuse state upon de-clustering of its target. We examined OFF-kinetics
164 of CluMPS upon light removal and declustering of Cry2 and another light-induced clustering
165 protein, BcLOV4⁵⁷. In both cases, CluMPS reverted back to a diffuse state with a half-life of
166 either ~11 min (Cry2 target) or ~100 s (BcLOV4 target), reflecting known differences in the OFF-
167 kinetics of these targets^{61,62}. Thus, CluMPS does not lock targets into condensates and can
168 dynamically report on their clustered state (**Supplementary Figure 6**).
169
170 **A stochastic model reveals important parameters for CluMPS activation**
171 To understand the key principles that govern CluMPS, we built an *in silico* model to rapidly
172 explore the experimental parameter space. We extended a kinetic Monte Carlo model of protein
173 clustering⁶³ to simulate interactions between two multivalent species, a ‘target’ and a ‘reporter’
174 (CluMPS) (**Figure 2A**). Each species moved freely within its 2D grid but could interact with
175 members of the opposite species near its corresponding grid position (**Figure 2B**). The valency
176 of each unit defined the maximum number of such cross-species interactions per unit. A binding
177 energy ΔE defined the strength of a single target:reporter interaction. Reporter units had a
178 valency of six to approximate the valency of CluMPS probes containing HOTag3. During each
179 simulation step, one target or reporter unit could move to an adjacent grid space. The likelihood
180 of movement p_{move} was determined by the enthalpy of cross-plane interactions, a function of ΔE
181 and the number and valency of current binding partners (**Figure 2B**, see **Methods** for more
182 details). Using this framework, we simulated through time the spatial distribution of targets and
183 reporters as a function of four system parameters: 1) binding energy (ΔE), 2) target cluster size,
184 3) the fraction of target that was in a cluster, since proteins clusters can exist in a distribution of
185 sizes within the cell, and 4) the concentrations of both target and reporter (**Figure 2C**). We
186 began each simulation with randomly placed target and reporter units and ran simulations until a
187 steady state of reporter condensates was reached. We then quantified the fraction of reporter

188 units that were part of a cluster at steady state. Simulations of these simple rules of motion and
189 interaction yielded large target/reporter condensates over time (**Figure 2D, Supplementary**
190 **Video 2**). Both higher ΔE and higher target valency drove stronger condensation, recapitulating
191 intuitive aspects of the CluMPS system (**Figure 2D,E**). Condensation increased sigmoidally with
192 increasing binding affinity, with a more switch-like relationship at higher target valencies (**Figure**
193 **2E**). Condensation was also sensitive to the fraction of target that was in a cluster (multivalent).
194 We modeled cluster size distributions by adding monomeric target units until a predefined
195 percentage of clustered targets was reached (from 25% to 100%). Increasing the amount of
196 target monomers (decreasing the percentage of target clusters) diminished condensation
197 because monomers that bound reporters lowered the likelihood of multivalent-multivalent
198 interactions required for condensation (**Figure 2F**). Our simulations also suggested that the
199 CluMPS strategy could robustly amplify clusters as small as tetramers, and, under ideal
200 conditions (high affinity, high percent clustered) even dimers and trimers, though to a lesser
201 extent (**Figure 2E,F**). Finally, our simulations suggested that CluMPS condensation would be
202 sensitive to the relative concentrations of target and reporter, which we simulated by varying the
203 number of target and reporter units in the simulation. Condensation was most robust when target
204 and reporter were present in roughly equal amounts but was disfavored when either was in large
205 excess (**Figure 2G**). Additionally, simulations with high concentrations of target and reporter
206 yielded condensation that was less sensitive to target:reporter affinity and target cluster size,
207 given appropriate target:reporter ratio (**Figure 2H**). Collectively, these simulations are consistent
208 with the established role of multivalency in driving phase separation and provide predictions for
209 how to optimize and interpret CluMPS behavior^{51,69,82}.
210

211 ***Optogenetic test systems validate model predictions***

212 We next sought to experimentally test our model predictions using two optogenetic clustering
213 systems to generate target clusters (**Figure 3A**). To test the role of affinity, we measured
214 amplification of Cry2-GFP using CluMPS reporters with distinct GFP-binding nanobodies of
215 different affinities: LaG17-CluMPS ($K_d = 50$ nM), LaG6-CluMPS (310 nM), and LaG18-CluMPS
216 (3800 nM) (**Figure 3B, Supplementary Figure 7**)^{64–66,68,70}. In agreement with predictions,
217 LaG17-CluMPS robustly amplified light-induced Cry2-GFP clusters, whereas the lower-affinity
218 LaG6-CluMPS and LaG18-CluMPS were progressively less effective, forming smaller and fewer
219 clusters after light stimulation (**Figure 3C, Supplementary Figure 7, Supplementary Video 3**).
220

221 To test the roles of target cluster size and distribution, we adopted a method to generate
222 stoichiometrically defined GFP clusters by concatemerizing the iLid protein (2-6mer “strings”,
223 iLidx2-iLidx6), which forms heterodimers with sspB under blue light^{69–71} (**Figure 3A, right**). In this
224 system, blue light transitioned GFP-sspB from a monomer to a cluster, with cluster size defined
225 by the string length. Co-transfection of the iRFP-iLid_{string}, GFP-sspB, and LaG17-CluMPS allowed
226 us to observe light-induced condensate formation with quantitative measures of expression of
227 each component (**Supplementary Figure 8**).
228

229 We used this system to confirm that cluster size, modeled by iLid_{string} length, correlated with the
230 magnitude of CluMPS amplification, as predicted by simulations (**Figure 3D,E**). Robust
231 condensation was observed in the presence of iLidx6 and was progressively weaker with smaller
232 string lengths (**Figure 3E, Supplementary Figure 8D**). The strong clustering in cells with iLidx6
233 was still lower compared to that observed in cells expressing Cry2-GFP, which forms clusters
234 with valencies $\gg 6$. In some cells, condensation could be observed with string sizes as small as
235 2 and 3, as predicted by our simulations. To further confirm these results, we co-expressed
236 LaG17-CluMPS with tandem GFPs (2X or 3X) on a single peptide chain, and we observed robust
237 clustering in most cells (**Supplementary Figure 9**). These results confirm that, under ideal
238 conditions (stable multimers, high CluMPS:target affinity, 100% multimerized), CluMPS can

239 report on target clusters as small as trimers and dimers. However, we expect that most 'real-
240 world' conditions will be less ideal, and that such small oligomers will be challenging to detect.
241

242 We assessed the role of cluster size distribution using the iLid strings system by taking
243 advantage of cell-to-cell variability in expression levels of each component. We estimated the
244 percentage of GFP-sspB in iLid_{string}-bound clusters by comparing the relative expression levels of
245 iRFP-iLid_{string} and GFP-sspB (**Figure 3F, Supplementary Figure 10**). For example, a high
246 sspB/iLid_{string} ratio resulted in a low percentage of GFP-sspB (the CluMPS target) clustered since
247 there remained an excess of monomeric, unbound GFP-sspB even after light stimulation (**Figure**
248 **3F,G, Supplementary Figure 10**). We poly-transfected GFP-sspB and iLid_{string} plasmids to
249 achieve uncorrelated expression and a wide range of sspB:iLid string ratios in a single pool of
250 cells⁷¹⁻⁷³ (**Supplementary Figure 11**). In line with simulations, we found that cells with a high
251 percentage of clustered target (50-100%, $0.5 < \text{sspB/iLid}_{\text{string}} < 2$) showed strong light-induced
252 condensation, whereas cells with 25-50% ($2 \leq \text{sspB/iLid}_{\text{string}} < 4$) showed less condensation, and
253 at $< 25\%$ ($\text{sspB/iLid}_{\text{string}} \geq 4$), condensation was not detectable (**Figure 3H, Supplementary**
254 **Figure 12**).
255

256 Finally, we examined how CluMPS condensation was influenced by expression levels of target
257 and reporter. We assayed a wide range of expression of LaG17-CluMPS and target for both
258 Cry2-GFP and GFPx5 (**Figure 3I,J, Supplementary Figure 13**). For light activated Cry2-GFP,
259 robust clustering was observed across expression levels, except in the case of 'low' Cry2-GFP
260 and 'high' CluMPS (**Figure 3J,K, Supplementary Figure 13C,D**). Additionally, condensation
261 decreased as the CluMPS:target ratio grew, as predicted by our simulations. Condensation was
262 more sensitive to concentrations with the GFPx5 target, which has lower valency than light-
263 activated Cry2-GFP and also does not self-associate. Here, robust condensation required
264 sufficient expression of both components (**Supplementary Figure 13E,F**). Condensation was
265 strongest at an intermediate CluMPS:GFPx5 ratio, with weaker condensation when relative
266 expression was biased too far towards either component (**Supplementary Figure 13G**).
267

268 To obtain a conservative estimate of the lower limit of target concentration required to trigger
269 CluMPS, we co-expressed a small target cluster (iRFP-ALFAx4) with nbALFA-GFP-HOTag3,
270 and we measured condensation as a function of target and reporter fluorescence that was
271 calibrated against known protein concentrations (**Supplementary Figure 14A-E**). Condensates
272 formed below the lower limit of imaging detection of iRFP-ALFAx4, ~800 nM, confirming that
273 CluMPS can operate at concentrations typical of endogenous proteins (**Supplementary Figure**
274 **14D**). We emphasize, however, that the limit of detection will vary as a function of cluster size,
275 distribution, target affinity, and ratio of target to reporter, as detailed above.
276

277

278 **CluMPS amplifies small clusters of pathological proteins**

279 To determine whether CluMPS enhances visualization of known protein oligomers, we tested
280 whether it could detect and amplify small aggregates of disease-associated proteins. These
281 target proteins were fused with GFP to allow amplification with LaG17-CluMPS (LaG17 binds
282 GFP with $K_d = 50$ nM).
283

284 The nucleocapsid (N) protein of SARS-CoV-2 can phase separate due to its self-affinity,
285 disordered regions, and RNA interactions⁷⁴. However, a GFP-N fusion appeared diffuse in HEK
286 293T cells, as previously observed⁷⁴, likely because N-protein condensates are small (**Figure**
287 **4A**). By contrast, co-expression with LaG17-CluMPS resulted in micron-scale aggregates of both
288 GFP-N and the reporter, observed in 100% of cells (**Figure 4A-C**).
289

290 We then tested CluMPS amplification of TDP-43, a nuclear protein that is found in neuronal
291 inclusions in ~97% of sporadic ALS patients, and whose aggregation is strongly associated with
292 ALS progression⁷⁴⁻⁷⁶. Because TDP-43 is a nuclear protein, we appended LaG17-CluMPS with a
293 nuclear localization sequence (NLS) at the C-terminus. GFP-TDP-43 was expressed in the
294 nucleus and, like N-GFP, was largely diffuse in HEK 293T cells under 40X confocal microscopy
295 (**Figure 4D**). By contrast, co-expression with nuclear-targeted LaG17-CluMPS increased the
296 detection of TDP-43 condensates from ~2% to ~80% of cells (**Figure 4D-F**), revealing the
297 underlying self-association tendencies of GFP-TDP-43. Phase separation was more evident in
298 the CluMPS channel, likely an artifact of differential expression levels and background
299 fluorescence of the target and reporter (**Figure 4D**).
300

301 Finally, we tested the ability of CluMPS to amplify condensates of EML4-ALK, an oncogenic
302 fusion protein commonly found in lung cancers^{74,84}. The EML4-ALK-GFP fusion alone was
303 observed to form condensates in only ~25% of transfected HEK 293T cells and remained diffuse
304 in the remaining 75% of cells (**Figure 4G-I**). However, co-expression with LaG17-CluMPS
305 yielded large condensates in virtually every cell (**Figure 4G-I**). Thus, in the absence of CluMPS,
306 GFP fusions of EML4-ALK form clusters that are too small to see above the diffuse GFP
307 background in most cells, and CluMPS can successfully detect and amplify these small clusters.
308

309 **Visualizing clusters of endogenous proteins**

310 Because CluMPS magnifies clusters of its binding partner, it can be applied to detect clusters of
311 endogenous proteins. This could be achieved either by using binding partners for the unmodified
312 target or by tagging the protein of interest with a custom binding epitope at the endogenous
313 locus. We tested the first strategy by designing a CluMPS reporter to amplify condensates of the
314 EML4-ALK oncogene in patient-derived H3122 lung cancer cells (**Figure 5A**). EML4-ALK drives
315 oncogenic signaling by the cytoplasmic aggregation and autophosphorylation of the ALK kinase
316 domain, which recruits adapter proteins including Grb2 and Gab1 to trigger downstream growth
317 signals⁷⁵. For the CluMPS binding domain, we used the proline rich domain (PRD) from Gab1
318 (amino acids 263-451), which binds Grb2⁸⁵, an essential component of EML4-ALK condensates⁷⁷
319 (**Figure 5A,B**). Thus Gab1(PRD)-CluMPS reports on Grb2 condensation as a proxy for EML4-
320 ALK condensation. In H3122 cells, we observed large condensates of Gab1(PRD)-CluMPS
321 (**Figure 5C,D**), whereas no condensation was observed in cells expressing a construct with
322 either no amplification domain (Gab1(PRD)-mCh) or no Grb2-binding domain (LaG17-CluMPS)
323 (**Supplementary Figure 15A,B**). EML4-ALK puncta that co-localized with Gab1(PRD)-CluMPS
324 were larger than those that did not (53 ± 2 vs. 11.0 ± 0.1 pixels, roughly 3.2 ± 0.12 vs 0.66 ± 0.01
325 μm^2), indicating successful CluMPS amplification of the endogenous condensates (**Figure 5D**,
326 **Supplementary Figure 16A-C**). CluMPS expression in H3122 cells that harbored a
327 fluorescently-tagged endogenous allele of Grb2 confirmed that Gab1(PRD)-CluMPS
328 condensates colocalized with both Grb2 and EML4-ALK (**Figure 5E**). Virtually every CluMPS
329 condensate ($97 \pm 1\%$, $N = 956$ condensates) overlapped with ALK immunostaining,
330 demonstrating high specificity (**Figure 5E**) whereas Gab1(PRD)-CluMPS was diffuse in cell lines
331 that lacked EML4-ALK (**Supplementary Figure 15C**). We observed CluMPS condensates in $89 \pm 4\%$ of
332 CluMPS-expressing cells ($N = 224$ cells), demonstrating high sensitivity.
333

334 The ability to visualize endogenous aggregates allowed us to track their dynamics in response to
335 the ALK inhibitor crizotinib (**Figure 5F, Supplementary Figure 16D-H, Supplementary Movie**
336 **4**). Although it is known that crizotinib blocks EML4-ALK activity and suppresses its
337 condensation, in part due to dissociation of Grb2⁵⁸, the kinetics and extent of condensate
338 dissolution has not been observed in living cancer cells. We found that, upon drug addition,
339 CluMPS condensate area rapidly decreased within 10 minutes, followed by a slow but
340 measurable decrease thereafter (**Figure 5G, Supplementary Figure 16D-H**). The half-life of the

341 initial decay of the CluMPS signal was ~4 minutes. This rate is ~4X faster than a recent
342 measurement of the rate of Grb2 dissociation from heterologously overexpressed EML4-ALK⁷⁸.
343 We validated this fast decay through a fixed-cell time course experiment and obtained similarly
344 fast decay of the EML4-ALK/CluMPS condensates ($t_{1/2} = 3.5$ minutes) (**Supplementary Figure**
345 **16G,H, Supplemental Figure 17**). This faster measured rate may reflect the differences in
346 measuring endogenous aggregates versus aggregates of overexpressed EML4-ALK, as
347 performed previously⁵⁷. We also observed that, despite extended drug treatment, ALKi did not
348 induce full dissociation of CluMPS condensates, in line with previous reports showing that EML4-
349 ALK (V1) condensates are relatively stable⁶¹. These residual CluMPS condensates were not
350 merely an artifact of CluMPS expression, since residual ALK clusters were also detected in
351 untransfected, drug-treated H3122 cells (**Supplementary Figure 16B-D**). The presence of
352 CluMPS condensates under these drug conditions suggests that the residual EML4-ALK clusters
353 retain a basal level of phosphorylation and signaling potential, which is required for the
354 colocalization of Grb2 and Gab1(PRD). Thus, CluMPS can visualize the dynamics of
355 endogenous protein assemblies and showcases potentially important differences between
356 measuring endogenous proteins in their naive context as compared to their exogenous
357 overexpression in unrelated cell types.
358

359 We next tested whether CluMPS could also amplify clusters of proteins that have been tagged at
360 their endogenous locus. Phase separation of the protein kinase A (PKA) regulatory subunit R1 α
361 was recently found to sequester intracellular cAMP and regulate PKA signaling²⁰. When
362 overexpressed, R1 α forms large condensates, but endogenous clustering is more difficult to
363 visualize²⁰. To apply CluMPS to endogenous R1 α , we first tagged R1 α with mClover3 at its
364 endogenous locus in HEK 293T cells (**Figure 5J, Supplemental Figure 18**)⁷⁵. Because
365 mClover3 is a GFP derivative, it served as an affinity tag for LaG17-CluMPS (**Figure 5H**).
366 Whereas R1 α :mClover3 looked diffuse under 40X magnification, co-expression of LaG17-
367 CluMPS yielded large condensates containing both CluMPS and mClover3 (**Figure 5I,J**).
368 Immunofluorescence confirmed that these condensates were enriched for R1 α / β (**Figure 5I**). As
369 before, CluMPS detection was sensitive (condensates were present in 89% of CluMPS positive
370 cells, N = 743 cells), and specific (94% of CluMPS condensates were enriched for R1 α / β , N =
371 1302 condensates). Endogenous tagging presents a straightforward strategy for amplifying
372 clusters of endogenous proteins, providing a generalizable strategy for using CluMPS to report
373 on arbitrary endogenous proteins with no further engineering of the reporter.
374

375 **Multiplexed amplification of distinct target clusters in single cells.**
376 Finally, we asked whether we could multiplex CluMPS reporters to magnify distinct clusters in the
377 same cell. We leveraged the fact that both HOTag3 and HOTag6 work as strong amplification
378 domains (**Figure 1, Supplementary Figure 1**) but do not cross-interact when co-expressed⁶³.
379 We generated a HOTag6-based CluMPS reporter using miRFP and LaG17 as the binding
380 domain (LaG17-CluMPS) to multiplex with a HOTag3-based reporter with mRuby2 and a
381 nanobody for the ALFA tag⁷⁵ (nbALFA-CluMPS) (**Figure 6A**). We co-expressed these two
382 constructs in cells with two distinct optogenetic clustering targets: ALFA-Cry2, which forms
383 clusters in the cytoplasm, or BcLOV4-GFP, which forms clusters at the membrane (**Figure**
384 **6B**)⁷⁷. Blue light triggered the appearance of distinct condensates in both the mRuby and iRFP
385 channels, reflecting amplification of the two distinct optogenetic clusters (**Figure 6C,D**,
386 **Supplementary Movie 5**). Condensates in the two channels did not overlap, with membrane-
387 associated BcLOV4 clusters more peripheral and Cry2 clusters more cytoplasmic, thus
388 demonstrating multiplexed cluster detection using orthogonal CluMPS probes (**Figure 6C,E**,
389 **Supplementary Figure 19**).
390
391

392 **Discussion**

393 The CluMPS reporter visualizes small protein clusters by amplifying them, with a sensitivity that
394 extends to small oligomers (3-4-mers) under appropriate conditions. Through simulations and
395 experiments, we showed that amplification is a function of concentration, affinity for the target,
396 target cluster size, and the fraction of target that is clustered. Although our work focused on
397 amplification of small clusters, CluMPS works over a large range of cluster sizes and thus will
398 find use to visualize a wide variety of protein assemblies. We demonstrate that CluMPS remains
399 diffuse when binding monomeric targets, allowing users to be confident that condensation of
400 CluMPS happens only when the CluMPS target is genuinely multimeric. Our CluMPS reporters
401 that bind GFP or ALFA-tag can be used to report on fusions of these tags —both heterologous
402 and endogenous — with arbitrary proteins of interest. Alternatively, CluMPS can be generated to
403 visualize the cluster dynamics of unmodified endogenous proteins and, with an activity-gated
404 binding domain, even downstream signaling (as with Gab1(PRD)-CluMPS, **Figure 5**). Finally, we
405 showed that the CluMPS reporter can be multiplexed using orthogonal CluMPS variants to
406 visualize multiple clusters in individual cells simultaneously.

407
408 CluMPS provides several advantages relative to existing methods to visualize aggregates in
409 cells. Unlike FRET, fluorescence anisotropy, fluorescence correlation, or super-resolution
410 techniques, CluMPS can be imaged using a single channel, has high signal-to-noise ratio, and
411 can be observed without complex microscopy and image processing. Further, CluMPS does not
412 require overexpression of the target protein and thus can avoid altering target concentration
413 levels, providing confidence that the detected clusters were in fact present in their physiological
414 context. A recent study developed a transcriptional reporter of protein aggregation called γ TRAP,
415 where the aggregation of a protein of interest sequestered a transcriptional activator and reduced
416 fluorescence from a transcriptional cassette⁸⁶. However, this approach required large, stable
417 aggregates of overexpressed protein and could only report on aggregates over long timescales
418 (~hours to days) in yeast. By contrast, CluMPS allows detection of endogenous, dynamic protein
419 clustering across a broad range of cluster types and sizes within the native cellular context of
420 mammalian cells (**Figure 3**).

421
422 A main limitation of CluMPS is that a negative result (no condensates) does not necessarily
423 indicate a lack of target clusters, but could alternatively be explained by factors including low
424 binding affinity for the target, low fraction of clustered target, or mismatch between reporter and
425 target expression. Because some of these factors will vary from cell to cell, CluMPS also cannot
426 be used for 'back-calculation' of features like the precise valency of the underlying target cluster.
427 Thus CluMPS is best interpreted as a ~binary cell-level reporter of a protein's cluster status.
428 Nevertheless, our simulations and experiments set forth design rules for CluMPS reporters and
429 provide context for interpreting CluMPS activity, for example when targeting endogenous
430 proteins whose cluster status and distribution are unknown. As is good practice for any live cell
431 reporter, conclusions from CluMPS should be validated by an orthogonal approach (e.g.
432 immunofluorescence). Another limitation is that CluMPS necessarily perturbs the clustering state
433 of its targets, changing the size and potentially the dynamics or even interaction partners of the
434 target clusters. Thus, proper controls are essential to account for these possibilities.
435 Nevertheless, we have not observed 'false positive' CluMPS signals where CluMPS would
436 induce target clustering where none existed, nor even substantial changes in the rates of cluster
437 formation or dissolution (**Supplementary Figures 2,3,5,6,9,15**). Finally, although we used
438 CluMPS probes that incorporate mCherry, mRuby, GFP, and miRFP, the identity of the
439 fluorescent protein can have a strong effect on clustering and phase separation of the
440 construct^{36,87}. Thus, the suitability of CluMPS variants with different fluorescent proteins must be
441 determined empirically.

442

443 We anticipate that the simplicity and high signal-to-noise ratio of CluMPS will enable numerous
444 unexplored applications, for example for screening drug libraries for compounds that disrupt
445 small neurodegenerative aggregates, or for detecting pathogenic aggregates in patient biopsies.
446 We thus expect CluMPS will enhance our understanding of the prevalence, relevance, and
447 dynamics of protein clusters that have previously been hard to see.

448

449 **Acknowledgements**

450 We thank Alex Hughes (Penn), Matthew Good (Penn) and Jin Zhang (UCSD) for helpful
451 discussions. We also thank Matthew Good and Ophir Shalem for providing genetic constructs
452 used in this work. This work was supported by the National Institutes of Health (R35GM138211
453 for L.J.B and D.G.M.; R35GM146877 for J.G.). Cell sorting was performed on a BD FACS Aria
454 Fusion that was obtained through NIH S10 1S10OD026986.

455


456

457 **Author Contributions**


458 T.R.M. and L.J.B conceived the study; T.R.M., A.I., D.G.M, A.A.P designed and performed
459 experiments; D.R. built the kinetic Monte-Carlo model; T.R.M. wrote the script for automated
460 analysis of fluorescent puncta; E.R. conceived and supervised the FCS experiments, which were
461 performed and analyzed by E.B; M.C.C. and J.G. generated the Grb2:mNG H3122 cell line.
462 T.R.M. analyzed data; T.R.M. and L.J.B. wrote the manuscript and made figures; L.J.B.
463 supervised the work.

464

465 **FIGURES**




466
467 **Figure 1: CLuMPS reporters amplify small protein oligomers. (A)** A CLuMPS reporter
468 (magenta) forms large condensates when its target (green) is clustered but remains diffuse when
469 the target is monomeric. **(B)** A CLuMPS reporter consists of a target binding domain, fluorescent
470 protein, and an amplification domain that facilitates phase separation in the presence of a
471 clustered target. **(C)** Cry2-GFP is diffuse in the dark but clusters when stimulated with blue light.
472 **(D)** Clusters of Cry2-GFP can be seen in high-expressing cells after 10 minutes of stimulation
473 with blue light, but low-expressing cells (red arrows) do not show visible clusters. Scale bars = 20
474 μm. **(E)** Cry2-GFP clustering is concentration dependent, and at low concentrations (green),
475 most light-induced Cry2-GFP clusters are too small to see. **(F)** CLuMPS variants with HOTag3 or
476 HOTag6 amplification domains successfully generated large phase-separated condensates upon
477 optogenetic clustering of Cry2-GFP, which was expressed at levels where clusters are not visible
478 in the absence of CLuMPS. A control reporter construct without an amplification domain (left)
479 shows no condensation. Data represent the means, error bars = 95% CI of approximately 20-50
480 cells per group. See also **(Supplementary Figure 1)**. Scale bar = 10 μm. **(G)** Quantification of
481 light-induced Cry2-GFP clusters, in the presence or absence of Lag17-CLuMPS (HOTag3) shows
482 CLuMPS-induced amplification of Cry2-GFP clustering including at low concentrations of Cry2-
483 GFP where, in the absence of CLuMPS, clustering is undetectable.



485 **Figure 2. Stochastic model of CluMPS condensation**

486 **(A)** Schematic of a kinetic Monte Carlo model of CluMPS/target interaction. CluMPS units
487 (magenta) and target units (green) populate separate but interacting 2D grid planes. Both
488 CluMPS and target units have a predetermined valency, which sets the number of adjacent units
489 on the opposite plane with which they can interact. **(B)** During each simulation step a random
490 unit is selected to move. The probability that the move is accepted is set by the enthalpy of
491 cross-plane interactions of the unit's initial state. The number of interactions is limited by the
492 unit's valency; i.e. if a unit set to move has four cross-plane neighbors, but a valency of three, the
493 enthalpy will be calculated as if there are only three neighbors (right-most panel). See **Methods**
494 for more details. **(C)** The model was used to understand how CluMPS parameters (binding
495 affinity ΔE , target cluster size, percent target clustered, and concentration) influenced
496 condensation. **(D)** Representative simulation results for different target valencies with constant
497 binding energy and 100% target clustered. Simulated CluMPS/target condensates form more
498 readily with larger target cluster sizes. See also **Supplementary Movie 2**. **(E)** Quantitation of
499 simulations that sampled different binding domain affinities across target cluster sizes.
500 Condensation increased with higher binding energy and larger target cluster sizes. Data points
501 represent means ± 1 s.d. of 10 simulations. Trend lines are sigmoidal curves of best fit for each
502 target cluster size. **(F)** Quantitation of simulations that sampled different distributions of target
503 clustering and target cluster sizes. Addition of monovalent target suppresses CluMPS:target
504 condensation for all target cluster sizes. Data points represent means ± 1 s.d. of 10 simulations.
505 **(G)** The effect of CluMPS and target concentrations was tested by varying the number of units of
506 each type. In simulations with target valency of 4 and target-reporter affinity of 2, increasing
507 number of target units from 100-500 increased condensation when 500 reporter units were
508 present, but decreased condensation when 100 reporter units were present. Data points
509 represent the mean percent of reporter units in condensates of 10 simulations ± 1 s.d. **(H)** Heat
510 map shows percent of reporter in condensates over all simulation parameters tested. Large 5x5
511 grid varies the number of target and reporter units used in each simulation, while each small 3x3
512 grid varies the affinity between target and reporter and the valency of target units. Color values
513 were generated from the mean percent of reporter units in condensates for 10 simulations at
514 each condition.

515



516
517

518 **Figure 3. CluMPS activation is determined by binding affinity, target cluster size, cluster
519 size distribution, and concentration.**

520 (A) Two optogenetic test systems were employed to empirically test the effects of cluster
521 parameters on CluMPS activation. Cry2-GFP was used to generate large clusters of variable
522 size. The iLid strings system was constructed to generate stoichiometrically-defined clusters.
523 Multiple iLids were fused on a single peptide ($iLid_{string}$), while sspB, which binds iLid in response
524 to blue light, was monomeric and fused to GFP. (B) Amplification of Cry2-GFP clusters using
525 CluMPS variants with different affinities of GFP-binding nanobody (C) LaG17 ($K_d = 50$ nM, left)
526 yielded robust amplification, LaG6 ($K_d = 310$ nM, center) showed weaker condensation, and
527 LaG18 ($K_d = 3800$ nM, right) did not produce condensation. Traces represent mean. Ribbons =
528 95% CI of approximately 100-200 cells per group. Scale bar = 20 μ m. (D) iLid strings of sizes 2-
529 6. (E) CluMPS activation in response to light-induced clustering of sspB-GFP with different iLid
530 string sizes. CluMPS condensation increases with valency of the iLid string; all strings produce
531 fewer condensates than Cry2-GFP. Data represents medians and quartiles of 80-200 cells per
532 group. (F) The percentage of light-induced clusters in a given cell was estimated by examining
533 the relative amounts of iLid string and GFP-sspB (see also **Supplementary Figure 10**). (G)
534 Representative image of sspB-GFP/CluMPS condensation in cells that have $iLid_{x6}$, GFP-sspB,
535 and LaG17-CluMPS and were stimulated with blue light for five minutes. Color coding indicates
536 the estimated percentage of GFP-sspB per cell that is clustered. Scale bar = 20 μ m. (H)
537 Quantification of relationship between light-induced CluMPS activation and the percentage of
538 clustered target. Robust formation of GFP-sspB/CluMPS condensates is observed when 50-
539 100% of sspB-GFP is clustered. Condensation is diminished when only < 25% of the target is
540 clustered, and is virtually undetectable when only < 25% of target is clustered. Dashed gray line
541 represents negative control of cells with CluMPS and GFP-sspB but no iLid string. Traces

542 represent means. Error bars = 95% CI of approximately 200 cells for the '50-100% clustered'
543 group and 40-60 cells for other groups. **(I)** Cry2-GFP with LaG17-CluMPS was used to
544 understand how relative concentration of target and CluMPS affect phase separation upon blue-
545 light induced multimerization of Cry2-GFP. **(J)** Representative images of CluMPS and Cry2-GFP
546 in four expression regimes (high target + high clumps, low target + high clumps, high target + low
547 CluMPS, and low target + low CluMPS). Clusters appeared in all regimes except low target +
548 high CluMPS. Scale bars = 20 μ m. **(K)** GFP (Cry2-GFP) and mCh (LaG17-mCh-HOTag3)
549 intensities of single cells transfected with both Cry2-GFP and CluMPS plotted with dot size
550 scaled to number of CluMPS condensates observed after 10 minute blue light stimulation. For
551 similar analysis with GFPx5 and ALFAx4, see **Supplementary Figures 13,14**)
552





Figure 4. CluMPS detects clustering of pathological proteins.


553
554
555 **(A)** SARS-CoV-2 nucleocapsid protein (N) with N-terminal GFP fusion is diffuse when expressed
556 alone but aggregates when co-expressed with CluMPS. Scale bar = 20 μ m. Quantification of
557 cluster area **(B)** and fraction of cells with detectable clusters **(C)** of GFP-N in the presence or
558 absence of CluMPS. **(D)** TDP-43 is a nuclear protein whose aggregation is associated with
559 amyotrophic lateral sclerosis (ALS). Scale bar = 20 μ m. A GFP-TDP43 fusion is diffuse in the
560 nucleus when expressed alone but forms large clusters when co-expressed with LaG-17
561 CluMPS fused to an NLS. Quantification of cluster area **(E)** and fraction of cells with detectable
562 clusters **(F)** of GFP-TDP43 in the presence or absence of LaG17-CluMPS(NLS). **(G)** EML4-ALK
563 is an oncoprotein that forms aggregates required for its oncogenic signaling. An EML4-ALK-GFP
564 fusion is clustered in few cells when expressed alone but robustly forms droplets when co-
565 expressed with LaG17-CluMPS. Scale bar = 20 μ m. Quantification of cluster area **(H)** and
566 fraction of cells with detectable clusters **(I)** of EML4-ALK-GFP in the presence or absence of
567 LaG17-CluMPS. Box-and-whisker plots in **(B,E,H)** represent median and quartiles from
568 approximately 20-50 cells per group. Vertical lines extend from quartiles $\pm 1.5^*$ (interquartile
569 range). Bar plots **(C,F,I)** represent frequency. Error bars = 95% confidence interval of
570 approximately 20-50 cells per group



571 **Figure 5. Detection of endogenous clustered proteins using two distinct strategies**

572 **(A)** EML4-ALK forms oncogenic protein condensates that drive oncogenic signaling.

573 Condensation and signaling require the downstream adapter Grb2, which recruits additional
 574 adapters including Gab1. **(B)** A CluMPS reporter to visualize endogenous EML4-ALK
 575 condensates was developed using the proline rich domain (PRD) from Gab1, which binds an
 576 SH3 domain of Grb2 (Gab1(PRD)-CluMPS). **(C)** Gab1(PRD)-CluMPS shows robust condensates
 577 in living EML4-ALK+ cancer cells (right). A Gab1(PRD)-mCh fusion is insufficient to visualize
 578 EML4-ALK condensates. Scale bar = 10 μm. **(D)** Immunostaining of ALK in H3122. Condensates
 579 are larger in cells containing CluMPS (see also **Supplementary Figure 16**). Scale bar = 10 μm.
 580 Plot shows distribution of cluster sizes (pixels) for EML4-ALK condensates that are colocalized
 581 with a CluMPS condensate (magenta) or not (grey). Data represents approximately 90,000 non-
 582 overlapped condensates and 1000 overlapped condensates. **(E)** Immunofluorescence imaging of
 583 Gab1(PRD)-CluMPS, Grb2:mNeonGreen2, and EML4-ALK in H3122 cells harboring
 584 endogenously tagged Grb2 (Grb2:mNG2). Condensates are enriched for all three species. Scale
 585 bar = 20 μm. **(F)** Live cell imaging of CluMPS condensates before and during ALK inhibition with
 586 1 μM crizotinib (see also **Supplementary Movie 4**). Scale bar = 10 μm. **(G)** Quantification of
 587 CluMPS dynamics. CluMPS condensate area remains stable for 30 minutes prior to drug
 588 treatment, then rapidly decreases upon treatment with ALKi. Half-lives derived from fitting data
 589 between 0 and 90 minutes to a single exponential decay. Trace represents mean. Ribbons =
 590 95% CI of 31 cells. **(H)** R1α, a regulatory subunit of the PKA holoenzyme, was tagged at the
 591 endogenous locus with mClover. (see **Supplementary Figure 18**). LaG17, which has high
 592 affinity for mClover, can be used in a CluMPS reporter (LaG17-mCherry-HOTag3) to report on
 593 clusters of PKA R1α via binding the fused mClover tag. **(I)** Images of fixed HEK 293T with
 594 mClover-tagged R1α with some cells transfected with CluMPS and stained for R1α/β. Cells with
 595 CluMPS have large condensates, while cells lacking CluMPS appear to have diffuse R1α.
 596 Condensates are enriched in all three species. LaG17-CluMPS showed high sensitivity against
 597 cells with mClover-tagged R1α (89% cells with CluMPS condensate) and specificity (94% of
 598 CluMPS condensates are colocalized with an R1α/β condensate). Scale bar = 20 μm. **(J)** Density
 599 plots show distribution of condensate area in cells with no CluMPS (N = 2832), low CluMPS (N =
 600 2428), or high CluMPS (N = 743), with text showing mean area of condensates (pixels) in all
 601 cells in each group.



617 **STAR Methods**

618

619 **RESOURCE AVAILABILITY**

620 **Lead Contact**

621 Requests can be made to the lead contact Lukasz Bugaj (bugaj@seas.upenn.edu).

622

623 **Materials Availability**

624 Select plasmids from this manuscript have been deposited on addgene

625 (https://www.addgene.org/Lukasz_Bugaj , ID 190024 , ID 190026)

626

627 **Data and Code Availability**

628

- All microscopy data available from the lead contact upon request.
- Code used to fit clusters throughout this manuscript and described in Supplementary Figure 20 and 21 is available on github (<https://github.com/BugajLab/Cluster-Fitting>, DOI: 10.5281/zenodo.10471925).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

634

635 **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**

636 Cell lines and cell culture

637 All cell lines were maintained in standard cell culture incubators at 37°C and 5% CO₂. Lenti X
638 HEK 293T cells and HeLa cells were cultured in DMEM containing 10% fetal bovine serum (FBS)
639 and 1% penicillin/streptomycin (P/S). H3122 cells were cultured in RPMI-1640 media containing
640 L-glutamine with 10% FBS and 1% P/S. For experiments, cells were seeded with P/S-free media
641 in 96 or 384 well plates coated with 10 µg/mL MilliporeSigma™ 597 Chemicon™ Human Plasma
642 Fibronectin Purified Protein in PBS. For 384 well plate experiments, 3000 HEK 293T cells or
643 H3122 cells were seeded in 50 µL of cell culture media in each well. For 96 well plate
644 experiments, 20,000 HEK 293T or H3122 cells were seeded in 200 µL of cell culture media in
645 each well.

646

647 **METHOD DETAILS**

648 Plasmid design and assembly

649 Constructs were assembled using Gibson assembly. DNA fragments and backbones were
650 generated via PCR and inserted into the backbone via HiFi cloning mix (New England Biolabs).
651 DNA sequences encoding GFP binding nanobodies (LaGs) were a kind gift from Dr. Michael P.
652 Rout ⁷⁹. HOTag6 and HOTag3 were obtained from pcDNA3-ERK-SPARK, which was a gift from
653 Xiaokun Shu (Addgene plasmid # 106921; <http://n2t.net/addgene:106921> ;
654 RRID:Addgene_106921) ⁸⁰. FUS(LC) (1-163), Xvelo, and LAF-1 RGG were kindly provided by
655 Matthew C. Good. iLid strings were adapted from mCherry-iLidx6, which was a gift from Takanari
656 Inoue (Addgene plasmid # 103779; <http://n2t.net/addgene:103779> ; RRID:Addgene_103779) ⁸¹.
657 GFP-TDP-43 was kindly provided by Ophir Shalem. SARS-CoV2-N protein sequence was
658 sourced from pLVX-EF1alpha-SARS-CoV-2-N-2xStrep-IRES-Puro, which was a kind gift from
659 Nevan Krogan (Addgene plasmid # 141391 ; <http://n2t.net/addgene:141391> ;
660 RRID:Addgene_141391). EML4-ALK-GFP was made through fusing EML4-ALK(V1) to GFP as
661 previously described ⁸². FTH1 was sourced from pCMV-SPORT6_FTH1, obtained from the High-
662 Throughput Screening (HTS) Core at Penn Medicine. The sequence encoding ALFA tag was
663 synthesized as a single strand DNA oligomer (Genewiz from Azenta Life Sciences), and
664 sequence encoding the ALFA binding nanobody (peptide elution, “nbALFA(PE)” variant) was
665 synthesized as a gBlock gene fragment (Integrated DNA Technologies) ⁸³. Gab1 (PRD) was
666 sourced from the human GAB1 cDNA sequence obtained from the High-Throughput Screening
667 (HTS) Core at Penn Medicine. PCSDest vectors for RNA synthesis were obtained from the

668 Zebrafish Core at Children's Hospital of Philadelphia. miRFP670, used in iLid_{strings} and LaG17-
669 miRFP670-HOTag6, was adapted from pCSII-EF-miRFP670v1-hGem(1/110), which was a gift
670 from Vladislav Verkhusha (Addgene plasmid # 80006 ; <http://n2t.net/addgene:80006> ;
671 RRID:Addgene_80006).

672
673 **RNA synthesis**
674 RNA transfection was used instead of DNA transfection for cell types that showed low efficiency
675 of plasmid DNA transfection. To generate RNA from the PCSDest expression plasmid, the
676 plasmid DNA was linearized with NotI and used as a template for RNA synthesis. RNA was
677 synthesized using the mMESSAGE mMACHINE™ (ThermoFisher Scientific) transcription kit with
678 SP6 RNA polymerase. RNA was spin-column purified using RNA Clean and Concentrator kit
679 (Zymo Research).
680

681 **Plasmid and RNA transfection**
682 HEK 293 T cells were transfected with DNA plasmids using Lipofectamine™ 3000 Transfection
683 Reagent (ThermoFisher Scientific) per manufacturer's protocol. Final transfection mixture was 1-
684 30 ng μ L⁻¹ DNA, 2% Lipofectamine™ reagent, 2% P3000 reagent and was brought to final
685 volume with Opti-MEM™ (ThermoFisher Scientific). Cells seeded in 384 well plates received
686 between 1 and 5 μ L of transfection mixture, and cells in 96 well plates received 10 μ L of
687 transfection mixture. Cells were imaged 24-60 hr after transfection. H3122 cells were transfected
688 with RNA using Lipofectamine™ MessengerMAX™ Transfection Reagent (ThermoFisher
689 Scientific), as RNA transfection was found to be more efficient than DNA transfection (described
690 above) in this cell type. Final transfection mixture was 10 ng μ L⁻¹ RNA, 2% Lipofectamine™
691 MessengerMAX™ reagent, and was brought to final volume with Opti-MEM™. Cells were
692 imaged 12-36 hr after RNA transfection. HEK 293 T cells and HeLa cells were also transfected
693 with Gab1(PRD) CluMPS RNA (as described above) for comparison with H3122 cells in **Figure**
694 **S15**.
695

696 **Live cell imaging**
697 Live-cell imaging was done using a Nikon Ti2E microscope equipped with a Yokagawa CSU-W1
698 spinning disk, 405/488/561/640nm laser lines, an sCMOS camera (Photometrics), a motorized
699 stage and an environmental chamber (Okolabs). HEK 293 T cells were imaged with a 40X oil
700 immersion objective at 37°C and 5% CO₂. In addition to exposure for imaging, experiments
701 requiring optogenetic stimulation of Cry2 and/or iLid-sspB received an additional 500 ms per field
702 of view per minute blue light exposure using the 488 nm laser line. For experiments where HEK
703 293 T cells were transfected with a construct containing miRFP670, the media was
704 supplemented with 25 μ M biliverdin hydrochloride (Sigma-Aldrich, product number 30891) 24
705 hours prior to imaging. H3122 cells were imaged with a 40X oil immersion objective. H3122 cells
706 were starved overnight with RPMI-1640 media containing L-glutamine and 1% P/S using a
707 BioTEK 405 plate washer. For live nuclear staining, H3122 cells were treated with 5 μ g/ml
708 Hoechst 33342 for 15 min before imaging. Cells were imaged for 30 minutes, then treated with
709 1 μ M crizotinib (Sigma-Aldrich, PZ0191) and imaged for 2 hours.
710

711 **Immunofluorescence staining**
712 Immediately after treatment, cells were fixed and stained as previously described ⁸⁸. Briefly, cells
713 were fixed for 10 min in 4% paraformaldehyde. Cells were permeabilized using PBS with 0.5%
714 Triton-X100 for 10 min. Cells were further permeabilized using 100% methanol at -20°C for 10
715 min and samples were blocked with 1% bovine serum albumin (Fisher, BP9706100) in PBS +
716 1% BSA for 1 hour at room temperature. Cells were then incubated in primary antibody diluted in
717 PBS + 1% BSA for 2 hours at room temperature or overnight at 4 °C (anti-ALK (D5F3), Cell
718 Signaling, catalog number 3633, 1:400 for ALK staining and anti-R1 α / β , Cell Signaling, catalog

719 number 3927, 1:100 for R1 α / β staining). Primary antibody was then washed with 0.1% Tween-20
720 in PBS (PBS-T). Cells were then incubated in secondary antibody diluted in PBS + 1%BSA as
721 recommended (IgG (H+L) Cross-Adsorbed Goat anti-Rabbit, DyLightTM 488, Invitrogen, catalog
722 number 35553, 1:500) and 4,6-diamidino-2-phenylindole (DAPI; ThermoFisher Scientific, catalog
723 number D1306, 300 nM) for 1 hour at room temperature and washed with PBS-T. Cells were
724 imaged in 50 μ L of PBS.

725
726 iLid strings experimental procedures
727 For testing CluMPS sensitivity with small multimers using iLid_{strings} (multiple iLid domains fused on
728 a single peptide, iLid_N: N = 2:6 iLids fused to miRFP670) transfected with GFP-sspB, it was
729 important to achieve a broad range of transfection conditions in order to sample a range of
730 sspB:iLid ratios across cells (**Figure 3F-H**). For these transfections, plasmids were ‘poly-
731 transfected’; each plasmid was mixed with transfection reagents in a separate tube from the
732 other plasmids and added to cells separately (**Supplementary Figure 11A**)⁷⁰. This resulted in
733 uncorrelated expression between components, permitting sampling of a wide range of sspB:iLid
734 ratio across cells (**Supplementary Figure 11B**).
735

736 iLid_{string} analysis
737 To determine the stoichiometric ratio of sspB:iLid, which sets the fraction of EGFP-sspB that
738 could bind sites on iLid multimers vs the fraction that remains monomeric, we used fusion of
739 EGFP-miRFP670 as a control (**Supplementary Figure 10A**). For each iLid_{string} experiment, a
740 separate well on the same plate was transfected with this EGFP-miRFP670 control, and imaged
741 with the same microscope parameters as the wells containing EGFP-sspB, miRFP670-iLid_{string},
742 and LaG17-CluMPS. With this control, the ratio EGFP:miRFP670 intensity in cells transfected
743 with EGFP-miRFP670, in which the number of EGFP and miRFP670 proteins are assumed to be
744 equal, could be calculated for many cells (**Supplementary Figure 10B,C**). The median ratio is
745 then used as a normalization factor to determine the stoichiometric ratio of EGFP:miRFP670 in
746 cells transfected with EGFP-sspB and miRFP670-iLid_{string} (**Supplementary Figure 10C,D**). With
747 this, it is trivial to calculate the sspB:iLid ratio given that EGFP-sspB are 1:1 and miRFP670:iLid
748 is known and dependent on the valency of the specific iLid_{string} that was transfected. The
749 percentage of GFP-sspB that was able to participate in clustering can then be estimated as
750 min(100, 100*(iLid/sspB)).
751

752 Estimating true concentration of nbALFA-GFP-HOTag3 and iRFP-ALFAx4
753 Imaging of 1)purified GFP of known concentration and 2) cells transfected with GFP-iRFP was
754 used to estimate the concentration of nbALFA-GFP-HOTag3 and iRFP-ALFAx4 in cells
755 transfected with both constructs (**Supplementary Figure 14B**). Wells not containing cells (but on
756 the same plate as the cells) were filled with 40 μ L of purified GFP (abcam, AB84191) at
757 concentrations of 25 μ M, 10 μ M, 5 μ M, 2.5 μ M, 1 μ M, and 0.5 μ M and imaged to obtain the
758 relationship between GFP intensity and GFP concentration (**Supplementary Figure 14C**). Also
759 on the same day and plate, cells transfected with GFP-iRFP were imaged to understand GFP
760 and iRFP relative intensities when present in equimolar amounts (See previous methods
761 paragraph, **Supplementary Figure 10**). With these two conversion factors (GFP intensity:GFP
762 concentration and GFP intensity:iRFP intensity), the concentration of GFP and iRFP in cells can
763 be estimated from their respective intensities.
764

765 Tagging R1 α at the endogenous locus
766 PKA regulatory subunit 1 α (PRKAR1A) was tagged at the endogenous locus using homology
767 independent intron tagging described by Serenrenik et al⁸¹. HEK293T cells were seeded in 12
768 well plates at a density of 250,000 cells per well. Each well was transfected 24 hours after
769 seeding with 467 ng of mClover3 generic donor plasmid, 140 ng of plasmid encoding the sgRNA

770 which targets the donor, 140 ng of plasmid encoding the sgRNA targeting PRKAR1A intronic
771 sequences, 252 ng of plasmid encoding Cas9. These plasmids were a kind gift from Dr. Ophir
772 Shalem, and were unmodified save for the insertion of the sgRNA sequence targeting
773 PRKAR1A. sgRNA sequences available in Key Resource Table. 24 hours after transfection, cells
774 were passed to a 6 well plate and seeded in media containing 5 μ g/mL blasticidin. After two
775 weeks of blasticidin selection, cells were sorted (BD FACS Aria Fusion) to further enrich
776 fluorescent-positive cells. Single cell colonies were made by seeding cells on 96 well plates with
777 a density of 0.5 cells/well to ensure wells contained 0-1 cells. Colonies were screened via
778 staining for PKA R1 α /R1 β (cell signaling #3927) and validated by western blot (**Supplementary**
779 **Figure 18**).

780
781 Western blot validation of PKA R1 α :mClover tagging
782 Wild-type and R1 α :mClover HEK293T cells were grown to confluence in a 10cm plate. Cells
783 were trypsinized, counted, and washed in room temperature PBS. 4x10⁶ of each cell type were
784 lysed in 500 μ L of lysis buffer (50mM Hepes 7.5, 10% glycerol, 150mM NaCl, 1% Triton X-100,
785 1mM EDTA, in H₂O). Lysis buffer was supplemented with a protease inhibitor just prior to lysis.
786 20 μ L of lysis was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Protein
787 separations were transferred onto a nitrocellulose membrane using the Trans-blot Turbo RTA
788 transfer kit (Bio-rad, #170-4270) according to the manufacturer's protocol. Membranes were
789 blocked in 5% milk in Tris buffer saline with 1% Tween-20 (TBS-T) for 1 hour and incubated
790 overnight with gentle shaking at 4°C with primary antibody against R1 α (CST #5675). Primary
791 antibody was used at a dilution of 1:1000 in TBS-T with 5% BSA. After washing with TBS-T,
792 membranes were incubated with secondary antibodies in TBS-T with 5% milk for 1 hr at room
793 temperature (Alexa Fluor® 790 AffiniPure Donkey Anti-Rabbit IgG (H+L) Jackson # 711-655-
794 152). Membranes were then imaged on the LI-COR Odyssey scanner.

795
796 Fluorescence correlation spectroscopy
797 For in-cell fluorescence correlation spectroscopy (FCS) measurements, HEK 293T cells
798 were plated in fibronectin coated 8-well NUNC chambers (Thermo Scientific, Rochester, NY) at a
799 cell density of 60,000 cells per well. Cells were transfected with 50 ng of GFP or GFPx5 and then
800 exchanged into 250- μ L phenol red-free media 24-hr after transfection. A portable stage-top
801 incubator (37 °C and 5% CO₂) was used during measurements. Imaging and FCS
802 measurements were made 24-72 hours after transfection.

803 Fluorescence lifetime imaging (FLIM) and FCS measurements were carried out on a
804 PicoQuant MicroTime 200 fluorescence microscope system equipped with a Flimbee Galvo
805 Scanner to allow for imaging (PicoQuant, Berlin, Germany). A 482 nm excitation laser set to 65%
806 of its maximum output, a pulse rate of 40 mGHz, was focused by a 60x Plan-Apo/1.4-NA water-
807 immersion objective (Olympus, Tokyo, Japan) with the coverslip correction collar set to 0.15.
808 Fluorescence emission was collected through the objective and focused onto a 150 μ m diameter
809 pinhole, then directed through a 525 \pm 35 nm band-pass filter and finally collected by an
810 avalanche photodiode detector. The Nunc chambers were mounted to a scanning stage
811 composed of a manually adjustable XY-axis stage, a Nano-ZL 100 piezo scanning stage (Mad
812 City Labs, Madison, WI). The Z-piezo stage and galvo-scanner allow for precision 2-dimensional
813 imaging of the X/Y, X/Z, and Y/Z planes. Image acquisition, data collection, and autocorrelation
814 analysis of intensity fluctuations were done using PicoQuant's accompanying software
815 SymPhoTime 64.

816 For FCS measurements, cells were first imaged in the X/Y plane and evaluated based on
817 the average photon count rate of the cell; cells with count rates of 150–600 kHz under the
818 conditions of our measurements were selected to move forward. For a selected cell, a better
819 quality FLIM image was first obtained in the X/Y plane, followed by an X/Z or Y/Z image. This
820 image was used to manually select placement of the focused laser in the cell cytoplasm,

821 avoiding positioning too close to the plasma membrane or nucleus. Generally, 3 to 5 FCS
822 measurements were made for each cell. For each FCS measurement, five autocorrelation curves
823 of five seconds each were collected and averaged together. Using a lab-written script in
824 MATLAB, the averaged autocorrelation curves were fit to a function for a single fluorescent
825 species undergoing Brownian motion in a three-dimensional Gaussian volume, with fits weighted
826 by the inverse square of the standard deviation:

$$G(\tau) = \frac{1}{N} \times \frac{1}{1 + \frac{\tau}{\tau_D}} \times \sqrt{\frac{1}{1 + \frac{s^2 \tau}{\tau_D}}}$$

827
828 where N is the average number of molecules in the focal volume, s is the ratio of the radial and
829 axial dimensions of the focal volume, and τ_D is the translational diffusion time. For each FCS
830 measurement, the molecular brightness of the fluorescent species interrogated – expressed as
831 counts per molecule (CPM) – was calculated by dividing the average intensity by N .

832
833 Cell segmentation

834 Cells were segmented using either CellProfiler for automated segmentation or by hand with a
835 custom MATLAB script. For CellProfiler segmentation, nuclei were identified. Then, cytoplasmic
836 fluorescence channels were gaussian and median filtered to prevent artifacts from segmenting
837 into clustered cells, and nuclear masks were expanded using the watershed method to segment
838 cell cytoplasms. For custom segmentation in MATLAB, a script was developed that allowed a
839 user to manually draw and modify cell masks. This script was used in cases where highly
840 accurate, low-throughput cell segmentation was needed. For quantifying clusters, segmentation
841 masks were fed forward into the cluster fitting algorithm (**see below**).

842
843 Fitting and quantifying clusters

844 Clusters were quantified from images of live and fixed cells using a custom MATLAB script. After
845 cell segmentation, clusters were quantified in each cell at each timepoint (**Supplementary**
846 **Figure 21**). The algorithm processes a single cell at a time, first normalizing the intensities within
847 the cell by subtracting the minimum intensity within the cell, then dividing by the median
848 background-subtracted intensity within the cell. Pixel intensities at the edge of the cell mask are
849 then propagated to the surrounding pixels outside of the cell mask to reduce contrast at the
850 edges of the cell (**Supplementary Figure 20C**)).

851 Selecting which pixels within the cell are included in a cluster is a two step process. First,
852 single high-intensity pixels at the center points of clusters are identified. To select these pixels, a
853 series of transforms is applied to the normalized cell image to remove background, suppress
854 noise, and enhance medium-high frequency objects (clusters). These are as follows:

- 855 • Gentle gaussian low-pass filter to suppress the highest frequency noise. This aims to
856 prevent single pixels that are randomly of high intensity from being enhanced by the
857 subsequent contrast enhancing steps.
- 858 • A top hat filter to suppress background; areas with low and uniform (longer than length
859 scales of ~5 pixels) values.
- 860 • Another gentle gaussian low-pass filter is used again to suppress the highest frequency
861 contrast, which tends to be noise rather than clusters
- 862 • Convolution with a 5x5 grid with the following values

863 ○

-1	-1	-1	-1	-1
-1	-1	-1	-1	-1

-1	-1	24	-1	-1
-1	-1	-1	-1	-1
-1	-1	-1	-1	-1

- 864 ○ This is a laplacian edge detector, and is typically used to enhance edges/areas of
865 contrast
866 ○ Resultant negative values are set to zero
867 ■ Values less than zero occur when a pixel has low intensity compared to its
868 surroundings. Suppression of such features enhances cluster-finding.

869 With this enhanced contrast image (**Supplementary Figure 20E,G**), points above a user-
870 defined threshold are identified. Quality control is performed to delete pixels from this list until
871 only the highest intensity pixel (in the raw fluorescent image, rather than the transformed image)
872 from each cluster is kept. This is defined as the cluster center (**Supplementary Figure 21C**).

873 Next, an expansion algorithm determines which pixels are included in the cluster. From
874 each identified cluster center, adjacent pixels are checked to be included or excluded from the
875 cluster as determined by an intensity cutoff. The cutoff is set by the local background in the area
876 surrounding the cluster or by the median of the cell (whichever is lower) multiplied by a scaling
877 factor set by the user. Pixels above this cutoff are included in the cluster, while pixels below the
878 cutoff are discarded (**Supplementary Figure 21D**). This occurs recursively, where adjacent
879 pixels to each included pixel are also checked to be included or excluded until all new neighbors
880 are below the threshold.

881 With this two step algorithm, we were able to extract information from cells on the single
882 cluster level, where the location, size, and intensity of each cluster in a cell is known.

884 Quality control in analysis of cluster fitting from automated fits

885 When clusters were fit on cells that were segmented in CellProfiler, rare errors occurred where
886 either a large fraction of a cell mask would be background or a mask would contain a cell, and
887 also a portion of a nearby and far brighter cell. In both cases, the algorithm would fit the entire
888 bright portion (either cell in a mask of mostly background, or the portion of the very bright cell
889 segmented with a dimmer cell) as a cluster. To address this, clusters fit from CellProfiler-
890 generated masks were discarded if they were greater than 500 pixels in area, as such clusters
891 were nearly exclusively caused by erroneous fits.

893 Analysis of Cry2-GFP + CluMPS variants

894 In all experiments where Cry2-GFP is expressed alone or with a CluMPS variant, cells are gated
895 for low expression of Cry2-GFP that do not form visible clusters after blue light stimulation. This
896 is demonstrated in **Figure 1**.

898 Data visualization

899 Clustering data were exported from MATLAB. Data were organized and visualized in Rstudio
900 using the tidyR package ⁸⁴.

902 Curve fitting

903 Gab1(PRD)-CluMPS cluster area quantification during treatment with crizotinib (**Figure 5**,
904 **Supplementary Figure 16**) were fit to exponential decay functions of the form

$$906 A \cdot \exp(-B \cdot t) + C$$

907 where t is time in minutes, and with the moment of crizotinib addition being t = 0 minutes. A
908 MATLAB function was written where the output was the sum of the squared difference between

910 an exponential decay of the form above and experimental data. Minimization of this function
911 generates the parameters for an exponential decay which most closely match the experimental
912 data. This process required 'guess' parameters to act as a starting point for the minimization
913 process. Guess parameters were set as A = the first experimental datapoint minus the lowest
914 experimental data point, B = $\log(2)/3.5$, and C = the lowest experimental data point. Identical
915 methods were used to fit decay of CluMPS condensate area and number in **Supplemental**
916 **Figure 6**.

917

918 Modeling

919 We generated a stochastic model of CluMPS amplification of target clustering in Python, using
920 the NumPy⁸⁵, Math, Statistics⁸⁶, and matplotlib⁸⁷ libraries. Our model modifies a previously
921 reported model by Dine et al that describes clustering of a single protein species²⁴. We extended
922 this model to simulate the kinetics of condensation of two multivalent species, the key principle
923 that drives CluMPS reporter activation upon clustering of a protein target, using a rejection
924 kinetic Monte Carlo process. The simulation contains two species, the target and reporter. In
925 each simulation there are 350 reporter units and 350 target units. At the simulation's initialization,
926 targets and reporters are randomly arranged on a 70 x 70 square grid. Each square on the grid
927 can contain up to one target and one reporter, but cannot contain two units of the same type.
928 Thus, the simulation can be conceptualized as two superimposed planes: one containing targets
929 and one containing reporters (**Figure 2A**). The model simulates kinetics through accepting or
930 rejecting movements of units on the grids (a random unit of either type and direction for it to
931 move are chosen at each step of the simulation). Whether a movement trajectory is accepted or
932 rejected is determined by a calculated probability for the move to happen, and a random number
933 roll (e.g. a move with a calculated probability of 60% is accepted if a randomly generated number
934 between 0 and 1 is less than 0.6, while the move is rejected if the number generated is greater
935 than 0.6). The probability of a move being accepted is calculated as a function of the enthalpy of
936 the interactions a unit experiences at the initial state when a move is proposed. Units can only
937 interact with units of the opposite species that are at the same or adjacent coordinates (**Figure**
938 **2A,B**). Both reporter and target units have a user-defined valency, which determines the
939 maximum number of cross-species interactions a unit is able to participate in. The reporter has a
940 valency of 6 in all simulations, while the target valency varies between simulations (between 2-6)
941 as indicated (**Figure 2C,D,E,F**). The valency of all units stays constant throughout the duration of
942 a simulation. Interactions between units have a user-defined interaction energy, ΔE . The
943 probability for a trajectory that moves a protein to a position not occupied by another of its type is
944 e^{-T} where T is the sum of the interaction energies from all the interactions that the protein
945 currently experiences (the minimum of the number of interactions and the units valency,
946 multiplied by the energy of a single interaction), $T = \min(\text{valency}, \# \text{ of neighbors}) * \Delta E$. The
947 following metrics are calculated every 2000 proposed steps: the total interaction strength of the
948 system (the sum of the enthalpies that each protein is currently experiencing), the percent
949 clustering (percent of reporter units that are in a cluster of six or more reporters), and finally the
950 rate of change of the total interaction strength from the previous interval to the current one. After
951 200 intervals have passed (200 intervals*200 steps per interval = 40,000 steps) the model also
952 sums the last 200 rates of change over their corresponding total interaction strengths. When this
953 sum is ≤ 0.01 , the simulation has reached steady state and ends, and the average percent
954 clustering over the last 100 intervals is reported.

955 For simulations in **Figure 2F**, in addition to multivalent target units, additional monovalent
956 target units were added to the simulation. For example, to run a simulation with 50% of clustered
957 target, 350 monovalent target units would be added to the simulation in addition to the 350
958 multivalent target units. Monovalent targets have the same interaction strength, ΔE , with reporter
959 units, can be randomly selected to move like any other unit, but can interact with a maximum of
960 one reporter unit. When a monovalent target is selected to move to a grid square containing a

961 multivalent target or vice versa, the probability that the two units switch places on the grid is set
962 as $e^{-(T_1+T_2)}$, where T_1 is the enthalpy of interactions for the first unit,
963 $T = \min(\text{valency}, \# \text{ of neighbors}) * \Delta E$, and T_2 is the enthalpy of interactions for the second
964 unit, calculated in the same way.

965 **Supplementary Movie Captions**

966

967 **Supplementary Movie 1. Screening amplification domains for CluMPS reporter.**

968 Representative time lapse videos of candidate CluMPS variants (magenta) co-transfected with
969 Cry2-GFP (green) and stimulated with blue light. CluMPS variants harbor different amplification
970 domains as indicated. Time is mm:ss. Scale bar = 20 μ m.

971

972 **Supplementary Movie 2. Representative simulations of stochastic model of CluMPS**
973 **amplification.** Each row shows motion of the target and reporter units under the indicated
974 simulation parameters. All rows have identical simulation parameters except for the valency of
975 the target, which is indicated to the left of each row. The right-most column shows the extent of
976 reporter clustering and the total interaction strength of the simulation. Simulations were stopped
977 once the interaction strength reached steady state. See **Methods** for more model details.

978

979 **Supplementary Movie 3. CluMPS:target affinity regulates CluMPS amplification.** LaG-
980 CluMPS variants with differing affinities were each co-transfected with Cry2-GFP and stimulated
981 with blue light. Higher-affinity CluMPS provided greater cluster amplification. Time is mm:ss.
982 Scale bar = 20 μ m.

983

984 **Supplementary Movie 4. Gab1(PRD)-CluMPS visualizes endogenous EML4-ALK**
985 **condensates and their shrinkage in response to ALK inhibitor.** Gab1(PRD)-CluMPS was
986 expressed in H3122 cancer cells, which harbor the EML4-ALK (V1) oncogene. ALK inhibitor
987 crizotinib (1 μ M) is added at t = 0 min. Scale bar = 20 μ m.

988

989 **Supplementary Movie 5. Multiplexed imaging of orthogonal CluMPS reporters against**
990 **distinct clustering targets in single cells.** Orthogonal CluMPS variants (LaG17-CluMPS,
991 nbALFA-CluMPS) were co-expressed with orthogonal blue-light-induced clustering systems
992 (BcLOV4-GFP and ALFA-Cry2) in the single cells. Blue light is applied at the beginning of the
993 video to induce clustering of both GFP and ALFA-tag. Distinct clusters are observed in both the
994 miRFP (LaG17 CluMPS, teal) and mRuby2 (nbALFA CluMPS, red) channels, suggesting
995 independent amplification of the distinct clusters. Time is mm:ss. Scale bar = 20 μ m.

996 **REFERENCES**

- 997 1. Marsh, J.A., and Teichmann, S.A. (2015). Structure, dynamics, assembly, and evolution of
998 protein complexes. *Annu. Rev. Biochem.* **84**, 551–575.
- 999 2. Chiesa, G., Kiriakov, S., and Khalil, A.S. (2020). Protein assembly systems in natural and
1000 synthetic biology. *BMC Biol.* **18**, 35.
- 1001 3. Banani, S.F., Lee, H.O., Hyman, A.A., and Rosen, M.K. (2017). Biomolecular condensates:
1002 organizers of cellular biochemistry. *Nat. Rev. Mol. Cell Biol.* **18**, 285–298.
- 1003 4. Shin, Y., and Brangwynne, C.P. (2017). Liquid phase condensation in cell physiology and
1004 disease. *Science* **357**. 10.1126/science.aaf4382.
- 1005 5. Zamudio, A.V., Dall'Agnese, A., Henninger, J.E., Manteiga, J.C., Afeyan, L.K., Hannett,
1006 N.M., Coffey, E.L., Li, C.H., Oksuz, O., Sabari, B.R., et al. (2019). Mediator Condensates
1007 Localize Signaling Factors to Key Cell Identity Genes. *Mol. Cell* **76**, 753-766.e6.
- 1008 6. Hartman, N.C., and Groves, J.T. (2011). Signaling clusters in the cell membrane. *Curr. Opin.*
1009 *Cell Biol.* **23**, 370–376.
- 1010 7. Riback, J.A., Katanski, C.D., Kear-Scott, J.L., Pilipenko, E.V., Rojek, A.E., Sosnick, T.R.,
1011 and Drummond, D.A. (2017). Stress-Triggered Phase Separation Is an Adaptive,
1012 Evolutionarily Tuned Response. *Cell* **168**, 1028-1040.e19.
- 1013 8. Guillén-Boixet, J., Kopach, A., Holehouse, A.S., Wittmann, S., Jahnel, M., Schlüßler, R.,
1014 Kim, K., Trussina, I.R.E.A., Wang, J., Mateju, D., et al. (2020). RNA-Induced Conformational
1015 Switching and Clustering of G3BP Drive Stress Granule Assembly by Condensation. *Cell*
1016 **181**, 346-361.e17.
- 1017 9. Yang, P., Mathieu, C., Kolaitis, R.-M., Zhang, P., Messing, J., Yurtsever, U., Yang, Z., Wu,
1018 J., Li, Y., Pan, Q., et al. (2020). G3BP1 Is a Tunable Switch that Triggers Phase Separation
1019 to Assemble Stress Granules. *Cell* **181**, 325-345.e28.
- 1020 10. Korkmazhan, E., Tompa, P., and Dunn, A.R. (2021). The role of ordered cooperative
1021 assembly in biomolecular condensates. *Nat. Rev. Mol. Cell Biol.* **22**, 647–648.
- 1022 11. Mehta, S., and Zhang, J. (2022). Liquid-liquid phase separation drives cellular function and
1023 dysfunction in cancer. *Nat. Rev. Cancer* **22**, 239–252.
- 1024 12. Su, Q., Mehta, S., and Zhang, J. (2021). Liquid-liquid phase separation: Orchestrating cell
1025 signaling through time and space. *Mol. Cell* **81**, 4137–4146.
- 1026 13. Castellana, M., Wilson, M.Z., Xu, Y., Joshi, P., Cristea, I.M., Rabinowitz, J.D., Gitai, Z., and
1027 Wingreen, N.S. (2014). Enzyme clustering accelerates processing of intermediates through
1028 metabolic channeling. *Nat. Biotechnol.* **32**, 1011–1018.
- 1029 14. Haass, C., and Selkoe, D.J. (2007). Soluble protein oligomers in neurodegeneration:
1030 lessons from the Alzheimer's amyloid beta-peptide. *Nat. Rev. Mol. Cell Biol.* **8**, 101–112.
- 1031 15. Lyon, A.S., Peebles, W.B., and Rosen, M.K. (2021). A framework for understanding the
1032 functions of biomolecular condensates across scales. *Nat. Rev. Mol. Cell Biol.* **22**, 215–235.
- 1033 16. Fusco, G., Chen, S.W., Williamson, P.T.F., Casella, R., Perni, M., Jarvis, J.A., Cecchi, C.,

- 1034 Vendruscolo, M., Chiti, F., Cremades, N., et al. (2017). Structural basis of membrane
1035 disruption and cellular toxicity by α -synuclein oligomers. *Science* 358, 1440–1443.
- 1036 17. Dine, E., Gil, A.A., Uribe, G., Brangwynne, C.P., and Toettcher, J.E. (2018). Protein Phase
1037 Separation Provides Long-Term Memory of Transient Spatial Stimuli. *Cell Syst* 6, 655–
1038 663.e5.
- 1039 18. Soto, C., and Pritzkow, S. (2018). Protein misfolding, aggregation, and conformational
1040 strains in neurodegenerative diseases. *Nat. Neurosci.* 21, 1332–1340.
- 1041 19. Koch, D. (2020). Homo-Oligomerisation in Signal Transduction: Dynamics, Homeostasis,
1042 Ultrasensitivity, Bistability. *J. Theor. Biol.* 499, 110305.
- 1043 20. Zhang, J.Z., Lu, T.-W., Stolerman, L.M., Tenner, B., Yang, J.R., Zhang, J.-F., Falcke, M.,
1044 Rangamani, P., Taylor, S.S., Mehta, S., et al. (2020). Phase Separation of a PKA
1045 Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling. *Cell* 0.
1046 10.1016/j.cell.2020.07.043.
- 1047 21. Ali, M.H., and Imperiali, B. (2005). Protein oligomerization: how and why. *Bioorg. Med.*
1048 *Chem.* 13, 5013–5020.
- 1049 22. Kaushik, S., and Cuervo, A.M. (2015). Proteostasis and aging. *Nat. Med.* 21, 1406–1415.
- 1050 23. Kumari, N., and Yadav, S. (2019). Modulation of protein oligomerization: An overview. *Prog.*
1051 *Biophys. Mol. Biol.* 149, 99–113.
- 1052 24. David, D.C., Ollikainen, N., Trinidad, J.C., Cary, M.P., Burlingame, A.L., and Kenyon, C.
1053 (2010). Widespread protein aggregation as an inherent part of aging in *C. elegans*. *PLoS*
1054 *Biol.* 8, e1000450.
- 1055 25. Farhadi, S.A., Liu, R., Becker, M.W., Phelps, E.A., and Hudalla, G.A. (2021). Physical tuning
1056 of galectin-3 signaling. *Proc. Natl. Acad. Sci. U. S. A.* 118. 10.1073/pnas.2024117118.
- 1057 26. Ben-Zvi, A., Miller, E.A., and Morimoto, R.I. (2009). Collapse of proteostasis represents an
1058 early molecular event in *Caenorhabditis elegans* aging. *Proc. Natl. Acad. Sci. U. S. A.* 106,
1059 14914–14919.
- 1060 27. Choi, M.L., and Gandhi, S. (2018). Crucial role of protein oligomerization in the
1061 pathogenesis of Alzheimer's and Parkinson's diseases. *FEBS J.* 285, 3631–3644.
- 1062 28. de Oliveira, G.A.P., Petronilho, E.C., Pedrote, M.M., Marques, M.A., Vieira, T.C.R.G., Cino,
1063 E.A., and Silva, J.L. (2020). The Status of p53 Oligomeric and Aggregation States in
1064 Cancer. *Biomolecules* 10. 10.3390/biom10040548.
- 1065 29. Douglass, A.D., and Vale, R.D. (2005). Single-molecule microscopy reveals plasma
1066 membrane microdomains created by protein-protein networks that exclude or trap signaling
1067 molecules in T cells. *Cell* 121, 937–950.
- 1068 30. Varma, R., Campi, G., Yokosuka, T., Saito, T., and Dustin, M.L. (2006). T cell receptor-
1069 proximal signals are sustained in peripheral microclusters and terminated in the central
1070 supramolecular activation cluster. *Immunity* 25, 117–127.
- 1071 31. Mo, G.C.H., Ross, B., Hertel, F., Manna, P., Yang, X., Greenwald, E., Booth, C., Plummer,

- 1072 1073 A.M., Tenner, B., Chen, Z., et al. (2017). Genetically encoded biosensors for visualizing live-cell biochemical activity at super-resolution. *Nat. Methods* 14, 427–434.
- 1074 1075 32. Goodsell, D.S., and Olson, A.J. (2000). Structural symmetry and protein function. *Annu. Rev. Biophys. Biomol. Struct.* 29, 105–153.
- 1076 1077 33. Keber, F.C., Nguyen, T., Brangwynne, C.P., and Wühr, M. (2021). Evidence for widespread cytoplasmic structuring into mesoscopic condensates. *bioRxiv*, 2021.12.17.473234. 10.1101/2021.12.17.473234.
- 1078 1079 34. Bugaj, L.J., Choksi, A.T., Mesuda, C.K., Kane, R.S., and Schaffer, D.V. (2013). Optogenetic protein clustering and signaling activation in mammalian cells. *Nat. Methods* 10, 249–252.
- 1080 1081 35. Lee, S., Park, H., Kyung, T., Kim, N.Y., Kim, S., Kim, J., and Heo, W.D. (2014). Reversible protein inactivation by optogenetic trapping in cells. *Nat. Methods* 11, 633–636.
- 1082 1083 36. Park, H., Kim, N.Y., Lee, S., Kim, N., Kim, J., and Heo, W.D. (2017). Optogenetic protein clustering through fluorescent protein tagging and extension of CRY2. *Nat. Commun.* 8, 30.
- 1084 1085 37. Shin, Y., Berry, J., Pannucci, N., Haataja, M.P., Toettcher, J.E., and Brangwynne, C.P. (2017). Spatiotemporal Control of Intracellular Phase Transitions Using Light-Activated optoDroplets. *Cell* 168, 159-171.e14.
- 1086 1087 1088 1089 38. Rust, M.J., Bates, M., and Zhuang, X. (2006). Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). *Nat. Methods* 3, 793–795.
- 1089 1090 1091 1092 1093 39. Chen, S.W., Drakulic, S., Deas, E., Ouberai, M., Aprile, F.A., Arranz, R., Ness, S., Roodveldt, C., Guilliams, T., De-Genst, E.J., et al. (2015). Structural characterization of toxic oligomers that are kinetically trapped during α -synuclein fibril formation. *Proc. Natl. Acad. Sci. U. S. A.* 112, E1994-2003.
- 1094 1095 1096 40. Bader, A.N., Hofman, E.G., Voortman, J., en Henegouwen, P.M.P. van B., and Gerritsen, H.C. (2009). Homo-FRET imaging enables quantification of protein cluster sizes with subcellular resolution. *Biophys. J.* 97, 2613–2622.
- 1097 1098 1099 41. Breedijk, R.M.P., Wen, J., Krishnaswami, V., Bernas, T., Manders, E.M.M., Setlow, P., Vischer, N.O.E., and Brul, S. (2020). A live-cell super-resolution technique demonstrated by imaging germinosomes in wild-type bacterial spores. *Sci. Rep.* 10, 5312.
- 1100 1101 1102 42. Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., and Selkoe, D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* 62, 788–801.
- 1103 1104 1105 43. Jungmann, R., Steinhauer, C., Scheible, M., Kuzyk, A., Tinnefeld, P., and Simmel, F.C. (2010). Single-molecule kinetics and super-resolution microscopy by fluorescence imaging of transient binding on DNA origami. *Nano Lett.* 10, 4756–4761.
- 1106 1107 1108 44. Ma, Y., Pandzic, E., Nicovich, P.R., Yamamoto, Y., Kwiatek, J., Pageon, S.V., Benda, A., Rossy, J., and Gaus, K. (2017). An intermolecular FRET sensor detects the dynamics of T cell receptor clustering. *Nat. Commun.* 8, 15100.
- 1109 1110 45. Sharma, P., Varma, R., Sarasij, R.C., Ira, Gousset, K., Krishnamoorthy, G., Rao, M., and Mayor, S. (2004). Nanoscale organization of multiple GPI-anchored proteins in living cell

- 1111 membranes. *Cell* 116, 577–589.
- 1112 46. Digman, M.A., Dalal, R., Horwitz, A.F., and Gratton, E. (2008). Mapping the number of
1113 molecules and brightness in the laser scanning microscope. *Biophys. J.* 94, 2320–2332.
- 1114 47. Ojosnegros, S., Cutrale, F., Rodríguez, D., Otterstrom, J.J., Chiu, C.L., Hortigüela, V.,
1115 Tarantino, C., Seriola, A., Mieruszynski, S., Martínez, E., et al. (2017). Eph-ephrin signaling
1116 modulated by polymerization and condensation of receptors. *Proc. Natl. Acad. Sci. U. S. A.*
1117 114, 13188–13193.
- 1118 48. Betzig, E., Patterson, G.H., Sougrat, R., Lindwasser, O.W., Olenych, S., Bonifacino, J.S.,
1119 Davidson, M.W., Lippincott-Schwartz, J., and Hess, H.F. (2006). Imaging intracellular
1120 fluorescent proteins at nanometer resolution. *Science* 313, 1642–1645.
- 1121 49. Huang, B. (2010). Super-resolution optical microscopy: multiple choices. *Curr. Opin. Chem.*
1122 Biol.
- 1123 50. Taslimi, A., Vrana, J.D., Chen, D., Borinskaya, S., Mayer, B.J., Kennedy, M.J., and Tucker,
1124 C.L. (2014). An optimized optogenetic clustering tool for probing protein interaction and
1125 function. *Nat. Commun.* 5, 4925.
- 1126 51. Zhang, Q., Huang, H., Zhang, L., Wu, R., Chung, C.-I., Zhang, S.-Q., Torra, J., Schepis, A.,
1127 Coughlin, S.R., Kornberg, T.B., et al. (2018). Visualizing Dynamics of Cell Signaling In Vivo
1128 with a Phase Separation-Based Kinase Reporter. *Mol. Cell* 69, 334–346.e4.
- 1129 52. Schuster, B.S., Reed, E.H., Parthasarathy, R., Jahnke, C.N., Caldwell, R.M., Bermudez,
1130 J.G., Ramage, H., Good, M.C., and Hammer, D.A. (2018). Controllable protein phase
1131 separation and modular recruitment to form responsive membraneless organelles. *Nat.*
1132 _{Commun.} 9, 2985.
- 1133 53. Bugaj, L.J., Spelke, D.P., Mesuda, C.K., Varedi, M., Kane, R.S., and Schaffer, D.V. (2015).
1134 Regulation of endogenous transmembrane receptors through optogenetic Cry2 clustering.
1135 *Nat. Commun.* 6, 6898.
- 1136 54. Elbaum-Garfinkle, S., Kim, Y., Szczepaniak, K., Chen, C.C.-H., Eckmann, C.R., Myong, S.,
1137 and Brangwynne, C.P. (2015). The disordered P granule protein LAF-1 drives phase
1138 separation into droplets with tunable viscosity and dynamics. *Proc. Natl. Acad. Sci. U. S. A.*
1139 112, 7189–7194.
- 1140 55. Patel, A., Lee, H.O., Jawerth, L., Maharana, S., Jahnel, M., Hein, M.Y., Stoynov, S.,
1141 Mahamid, J., Saha, S., Franzmann, T.M., et al. (2015). A Liquid-to-Solid Phase Transition of
1142 the ALS Protein FUS Accelerated by Disease Mutation. *Cell* 162, 1066–1077.
- 1143 56. Murthy, A.C., Dignon, G.L., Kan, Y., Zerze, G.H., Parekh, S.H., Mittal, J., and Fawzi, N.L.
1144 (2019). Molecular interactions underlying liquid-liquid phase separation of the FUS low-
1145 complexity domain. *Nat. Struct. Mol. Biol.* 26, 637–648.
- 1146 57. Fridy, P.C., Li, Y., Keegan, S., Thompson, M.K., Nudelman, I., Scheid, J.F., Oeffinger, M.,
1147 Nussenzweig, M.C., Fenyö, D., Chait, B.T., et al. (2014). A robust pipeline for rapid
1148 production of versatile nanobody repertoires. *Nat. Methods* 11, 1253–1260.
- 1149 58. Götzke, H., Kilisch, M., Martínez-Carranza, M., Sograte-Idrissi, S., Rajavel, A.,

- 1150 Schlichthaerle, T., Engels, N., Jungmann, R., Stenmark, P., Opazo, F., et al. (2019). The
1151 ALFA-tag is a highly versatile tool for nanobody-based bioscience applications. *Nat.*
1152 *Commun.* **10**, 4403.
- 1153 59. Bracha, D., Walls, M.T., Wei, M.-T., Zhu, L., Kurian, M., Avalos, J.L., Toettcher, J.E., and
1154 Brangwynne, C.P. (2018). Mapping Local and Global Liquid Phase Behavior in Living Cells
1155 Using Photo-Oligomerizable Seeds. *Cell* **175**, 1467-1480.e13.
- 1156 60. Pal, A.A., Benman, W., Mumford, T.R., Huang, Z., Chow, B.Y., and Bugaj, L.J. (2023).
1157 Optogenetic clustering and membrane translocation of the BcLOV4 photoreceptor. *Proc.*
1158 *Natl. Acad. Sci. U. S. A.* **120**, e2221615120.
- 1159 61. Guntas, G., Hallett, R.A., Zimmerman, S.P., Williams, T., Yumerefendi, H., Bear, J.E., and
1160 Kuhlman, B. (2015). Engineering an improved light-induced dimer (iLID) for controlling the
1161 localization and activity of signaling proteins. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 112–117.
- 1162 62. Nakamura, H., Lee, A.A., Afshar, A.S., Watanabe, S., Rho, E., Razavi, S., Suarez, A., Lin,
1163 Y.-C., Tanigawa, M., Huang, B., et al. (2018). Intracellular production of hydrogels and
1164 synthetic RNA granules by multivalent molecular interactions. *Nat. Mater.* **17**, 79–89.
- 1165 63. Gam, J.J., DiAndreth, B., Jones, R.D., Huh, J., and Weiss, R. (2019). A “poly-transfection”
1166 method for rapid, one-pot characterization and optimization of genetic systems. *Nucleic*
1167 *Acids Res.* **47**, e106.
- 1168 64. Iserman, C., Roden, C.A., Boerneke, M.A., Sealfon, R.S.G., McLaughlin, G.A., Jungreis, I.,
1169 Fritch, E.J., Hou, Y.J., Ekena, J., Weidmann, C.A., et al. (2020). Genomic RNA Elements
1170 Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. *Mol. Cell* **80**, 1078-1091.e6.
- 1171 65. Cubuk, J., Alston, J.J., Incicco, J.J., Singh, S., Stuchell-Brereton, M.D., Ward, M.D.,
1172 Zimmerman, M.I., Vithani, N., Griffith, D., Wagoner, J.A., et al. (2021). The SARS-CoV-2
1173 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. *Nat. Commun.*
1174 **12**, 1936.
- 1175 66. Perdikari, T.M., Murthy, A.C., Ryan, V.H., Watters, S., Naik, M.T., and Fawzi, N.L. (2020).
1176 SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs.
1177 *EMBO J.* **39**, e106478.
- 1178 67. Mammen, M., Choi, S.-K., and Whitesides, G.M. (1998). Polyvalent Interactions in Biological
1179 Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. *Angew.*
1180 *Chem. Int. Ed Engl.* **37**, 2754–2794.
- 1181 68. Savastano, A., Ibáñez de Opakua, A., Rankovic, M., and Zweckstetter, M. (2020).
1182 Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing
1183 condensates. *Nat. Commun.* **11**, 6041.
- 1184 69. Li, P., Banjade, S., Cheng, H.-C., Kim, S., Chen, B., Guo, L., Llaguno, M., Hollingsworth,
1185 J.V., King, D.S., Banani, S.F., et al. (2012). Phase transitions in the assembly of multivalent
1186 signalling proteins. *Nature* **483**, 336–340.
- 1187 70. Carlson, C.R., Asfaha, J.B., Ghent, C.M., Howard, C.J., Hartooni, N., Safari, M., Frankel,
1188 A.D., and Morgan, D.O. (2020). Phosphoregulation of Phase Separation by the SARS-CoV-
1189 2 N Protein Suggests a Biophysical Basis for its Dual Functions. *Mol. Cell* **80**, 1092-1103.e4.

- 1190 71. Johnson, B.S., Snead, D., Lee, J.J., McCaffery, J.M., Shorter, J., and Gitler, A.D. (2009).
1191 TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations
1192 accelerate aggregation and increase toxicity. *J. Biol. Chem.* **284**, 20329–20339.
- 1193 72. Fang, Y.-S., Tsai, K.-J., Chang, Y.-J., Kao, P., Woods, R., Kuo, P.-H., Wu, C.-C., Liao, J.-Y.,
1194 Chou, S.-C., Lin, V., et al. (2014). Full-length TDP-43 forms toxic amyloid oligomers that are
1195 present in frontotemporal lobar dementia-TDP patients. *Nat. Commun.* **5**, 4824.
- 1196 73. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T.,
1197 Bruce, J., Schuck, T., Grossman, M., Clark, C.M., et al. (2006). Ubiquitinated TDP-43 in
1198 frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**, 130–133.
- 1199 74. Tulpule, A., Guan, J., Neel, D.S., Allegakoen, H.R., Lin, Y.P., Brown, D., Chou, Y.-T., Heslin,
1200 A., Chatterjee, N., Perati, S., et al. (2021). Kinase-mediated RAS signaling via
1201 membraneless cytoplasmic protein granules. *Cell* **184**, 2649-2664.e18.
- 1202 75. Gonzalez-Martinez, D., Roth, L., Mumford, T.R., Tulpule, A., Bivona, T.G., and Bugaj, L.J.
1203 (2022). Oncogenic protein condensates modulate cell signal perception and drug tolerance.
1204 *bioRxiv*, 2022.02.02.478845. 10.1101/2022.02.02.478845.
- 1205 76. Sampson, J., Richards, M.W., Choi, J., Fry, A.M., and Bayliss, R. (2021). Phase-separated
1206 foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
1207 *EMBO Rep.* **22**, e53693.
- 1208 77. Che, D.L., Duan, L., Zhang, K., and Cui, B. (2015). The Dual Characteristics of Light-
1209 Induced Cryptochrome 2, Homo-oligomerization and Heterodimerization, for Optogenetic
1210 Manipulation in Mammalian Cells. *ACS Synth. Biol.* **4**, 1124–1135.
- 1211 78. Serebrenik, Y.V., Sansbury, S.E., Kumar, S.S., Henao-Mejia, J., and Shalem, O. (2019).
1212 Efficient and flexible tagging of endogenous genes by homology-independent intron
1213 targeting. *Genome Res.* **29**, 1322–1328.
- 1214 79. Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G.,
1215 Hayes, A., Henry, L., Hester, J., et al. (2019). Welcome to the tidyverse. *J. Open Source
1216 Softw.* **4**, 1686.
- 1217 80. Harris, C.R., Millman, K.J., van der Walt, S.J., Gommers, R., Virtanen, P., Cournapeau, D.,
1218 Wieser, E., Taylor, J., Berg, S., Smith, N.J., et al. (2020). Array programming with NumPy.
1219 *Nature* **585**, 357–362.
- 1220 81. Van Rossum, G., and Python Development Team (2018). The Python Library Reference:
1221 Release 3.6.4 - Book 1 of 2 (12th Media Services).
- 1222 82. Choi, J.-M., Holehouse, A.S., and Pappu, R.V. (2020). Physical Principles Underlying the
1223 Complex Biology of Intracellular Phase Transitions. *Annu. Rev. Biophys.* **49**, 107–133.
- 1224 83. Hunter, J.D. (2007). Matplotlib: A 2D Graphics Environment. *Comput. Sci. Eng.* **9**, 90–95.
- 1225 84. Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C.M.,
1226 Okimoto, R.A., Lin, L., Neel, D.S., Sabnis, A., et al. (2015). RAS-MAPK dependence
1227 underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. *Nat. Med.* **21**,
1228 1038.

- 1229 85. McDonald, C.B., Seldeen, K.L., Deegan, B.J., Bhat, V., and Farooq, A. (2011). Binding of
1230 the cSH3 domain of Grb2 adaptor to two distinct RXXK motifs within Gab1 docker employs
1231 differential mechanisms. *J. Mol. Recognit.* 24, 585–596.
- 1232 86. Newby, G.A., Kiriakov, S., Hallaci, E., Kayatekin, C., Tsvetkov, P., Mancuso, C.P., Bonner,
1233 J.M., Hesse, W.R., Chakrabortee, S., Manogaran, A.L., et al. (2017). A Genetic Tool to
1234 Track Protein Aggregates and Control Prion Inheritance. *Cell* 171, 966-979.e18.
- 1235 87. Huang, Z., Benman, W., Dong, L., and Bugaj, L.J. (2023). Rapid optogenetic clustering of a
1236 cytoplasmic BcLOV4 variant. *bioRxiv*, 2023.09.14.557726. 10.1101/2023.09.14.557726.
- 1237 88. Bugaj, L.J., and Lim, W.A. (2019). High-throughput multicolor optogenetics in microwell
1238 plates. *Nat. Protoc.* 14, 2205–2228.

1239